JP2020522560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522560A5 JP2020522560A5 JP2019567995A JP2019567995A JP2020522560A5 JP 2020522560 A5 JP2020522560 A5 JP 2020522560A5 JP 2019567995 A JP2019567995 A JP 2019567995A JP 2019567995 A JP2019567995 A JP 2019567995A JP 2020522560 A5 JP2020522560 A5 JP 2020522560A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- composition
- subject
- over
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023030625A JP2023071826A (ja) | 2017-06-06 | 2023-03-01 | 過活動膀胱を治療するためのビベグロンの使用 |
| JP2025005498A JP2025063196A (ja) | 2017-06-06 | 2025-01-15 | 過活動膀胱を治療するためのビベグロンの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515996P | 2017-06-06 | 2017-06-06 | |
| US62/515,996 | 2017-06-06 | ||
| US201862635146P | 2018-02-26 | 2018-02-26 | |
| US62/635,146 | 2018-02-26 | ||
| US201862637961P | 2018-03-02 | 2018-03-02 | |
| US62/637,961 | 2018-03-02 | ||
| PCT/IB2018/054069 WO2018224989A1 (en) | 2017-06-06 | 2018-06-06 | Use of vibegron to treat overactive bladder |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030625A Division JP2023071826A (ja) | 2017-06-06 | 2023-03-01 | 過活動膀胱を治療するためのビベグロンの使用 |
| JP2025005498A Division JP2025063196A (ja) | 2017-06-06 | 2025-01-15 | 過活動膀胱を治療するためのビベグロンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522560A JP2020522560A (ja) | 2020-07-30 |
| JP2020522560A5 true JP2020522560A5 (enExample) | 2021-07-26 |
| JP7682605B2 JP7682605B2 (ja) | 2025-05-26 |
Family
ID=62815097
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567995A Active JP7682605B2 (ja) | 2017-06-06 | 2018-06-06 | 過活動膀胱を治療するためのビベグロンの使用 |
| JP2023030625A Pending JP2023071826A (ja) | 2017-06-06 | 2023-03-01 | 過活動膀胱を治療するためのビベグロンの使用 |
| JP2025005498A Pending JP2025063196A (ja) | 2017-06-06 | 2025-01-15 | 過活動膀胱を治療するためのビベグロンの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030625A Pending JP2023071826A (ja) | 2017-06-06 | 2023-03-01 | 過活動膀胱を治療するためのビベグロンの使用 |
| JP2025005498A Pending JP2025063196A (ja) | 2017-06-06 | 2025-01-15 | 過活動膀胱を治療するためのビベグロンの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12102638B2 (enExample) |
| EP (2) | EP3634420A1 (enExample) |
| JP (3) | JP7682605B2 (enExample) |
| KR (2) | KR20200012949A (enExample) |
| CN (3) | CN117695287A (enExample) |
| AU (2) | AU2018282104B2 (enExample) |
| BR (1) | BR112019025636A2 (enExample) |
| CA (1) | CA3064989A1 (enExample) |
| CL (1) | CL2019003533A1 (enExample) |
| IL (2) | IL317220A (enExample) |
| MX (1) | MX2022015629A (enExample) |
| PH (1) | PH12019502651A1 (enExample) |
| WO (1) | WO2018224989A1 (enExample) |
| ZA (1) | ZA202000028B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3085745A1 (en) * | 2017-12-21 | 2019-06-27 | Kyorin Pharmaceutical Co., Ltd. | An agent for treating nocturnal pollakiuria |
| EP3890743A1 (en) * | 2018-12-05 | 2021-10-13 | Urovant Sciences GmbH | Vibegron for the treatment of overactive bladder symptoms |
| JP2022524576A (ja) * | 2019-03-18 | 2022-05-09 | ウロバント サイエンシズ ゲーエムベーハー | 過活動膀胱を処置するためのビベグロンの使用 |
| DE102020124101A1 (de) | 2020-02-04 | 2021-08-05 | Samsung Electronics Co., Ltd. | Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren |
| TW202239412A (zh) * | 2020-12-22 | 2022-10-16 | 瑞士商優洛凡特科學公司 | 使用維貝格隆（ｖｉｂｅｇｒｏｎ）並監測地高辛（ｄｉｇｏｘｉｎ）以治療膀胱過動症的方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1028111T3 (da) | 1997-10-17 | 2004-09-20 | Yamanouchi Pharma Co Ltd | Amidderivater eller salte heraf |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| GB0015246D0 (en) * | 2000-06-22 | 2000-08-16 | Astrazeneca Ab | Method for the treatment of urinary incontinence |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US7342117B2 (en) | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| DOP2003000587A (es) | 2002-02-27 | 2003-08-30 | Pfizer Prod Inc | AGONISTAS DEL RECEPTOR ß3-ADRENERGICO |
| AU2003284700B2 (en) | 2002-11-07 | 2009-05-28 | Astellas Pharma Inc. | Remedy for overactive bladder comprising acetic acid anlide derivatives as the active ingredient |
| ES2309513T3 (es) | 2003-05-05 | 2008-12-16 | Kissei Pharmaceutical Co., Ltd. | Uso de derivados de acido fenoxiacetico para tratar vejiga hiperactiva. |
| FR2874011B1 (fr) | 2004-08-03 | 2007-06-15 | Sanofi Synthelabo | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| WO2008128968A1 (en) | 2007-04-19 | 2008-10-30 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 |
| CN101855342B (zh) | 2007-09-13 | 2013-07-10 | 科德克希思公司 | 用于还原苯乙酮的酮还原酶多肽 |
| WO2009057685A1 (ja) | 2007-11-02 | 2009-05-07 | Astellas Pharma Inc. | 過活動膀胱治療用医薬組成物 |
| PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| WO2010025085A2 (en) | 2008-08-29 | 2010-03-04 | Codexis, Inc. | Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one |
| BR112012007829A2 (pt) | 2009-10-07 | 2015-09-22 | Merck Sharp & Dohme | método para tratar bexiga hiperativa, e, composição farmacêutica. |
| JP5812500B2 (ja) | 2010-04-30 | 2015-11-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規なβ３アドレナリン作動性受容体アゴニスト |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| PE20131341A1 (es) | 2010-08-03 | 2013-12-07 | Altherx Inc | Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva |
| KR20200003245A (ko) | 2011-10-14 | 2020-01-08 | 어레이 바이오파마 인크. | 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물 |
| ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
| EP2770996B1 (en) | 2011-10-27 | 2016-09-28 | Merck Sharp & Dohme Corp. | Process for making beta 3 agonists and intermediates |
| WO2013074650A1 (en) | 2011-11-18 | 2013-05-23 | Codexis, Inc. | Biocatalysts for the preparation of hydroxy substituted carbamates |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| UA112028C2 (uk) | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| LT2968269T (lt) | 2013-03-15 | 2019-10-25 | Merck Sharp & Dohme | Beta 3 agonistų ir tarpinių junginių gamybos būdas |
| KR20170086659A (ko) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
| PL3365321T3 (pl) | 2015-10-23 | 2024-03-25 | B3Ar Therapeutics, Inc. | Jon obojnaczy solabegronu i jego zastosowania |
| EP3463312A4 (en) | 2016-06-03 | 2020-02-05 | Velicept Therapeutics, Inc. | DOSAGE DIAGRAMS FOR BETA-3 ADRENERGIC RECEPTOR AGONISTS AND ANTI-MUSCARIN AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY SYMPTOMS AND VESICAL HYPERACTIVITY |
| US20170348263A1 (en) | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| US20210077496A1 (en) | 2017-06-06 | 2021-03-18 | Urovant Sciences Gmbh | Dosing of vibegron for treatment of overactive bladder |
| CA3085745A1 (en) | 2017-12-21 | 2019-06-27 | Kyorin Pharmaceutical Co., Ltd. | An agent for treating nocturnal pollakiuria |
| TW202015692A (zh) | 2018-05-23 | 2020-05-01 | 瑞士商優洛凡特科學公司 | 維貝格龍（ｖｉｂｅｇｒｏｎ）於治療與腸躁症候群相關之疼痛之用途 |
| EP3890743A1 (en) | 2018-12-05 | 2021-10-13 | Urovant Sciences GmbH | Vibegron for the treatment of overactive bladder symptoms |
| JP2022524576A (ja) | 2019-03-18 | 2022-05-09 | ウロバント サイエンシズ ゲーエムベーハー | 過活動膀胱を処置するためのビベグロンの使用 |
| TW202239412A (zh) | 2020-12-22 | 2022-10-16 | 瑞士商優洛凡特科學公司 | 使用維貝格隆（ｖｉｂｅｇｒｏｎ）並監測地高辛（ｄｉｇｏｘｉｎ）以治療膀胱過動症的方法 |
| US20240148735A1 (en) | 2021-02-16 | 2024-05-09 | Urovant Sciences Gmbh | Methods of treating heart failure with vibegron |
-
2018
- 2018-06-06 AU AU2018282104A patent/AU2018282104B2/en active Active
- 2018-06-06 JP JP2019567995A patent/JP7682605B2/ja active Active
- 2018-06-06 IL IL317220A patent/IL317220A/en unknown
- 2018-06-06 KR KR1020197038625A patent/KR20200012949A/ko not_active Ceased
- 2018-06-06 US US16/620,179 patent/US12102638B2/en active Active
- 2018-06-06 CN CN202311666478.3A patent/CN117695287A/zh active Pending
- 2018-06-06 CN CN201880045540.8A patent/CN110869022A/zh active Pending
- 2018-06-06 CN CN202311666042.4A patent/CN117695286A/zh active Pending
- 2018-06-06 WO PCT/IB2018/054069 patent/WO2018224989A1/en not_active Ceased
- 2018-06-06 BR BR112019025636-9A patent/BR112019025636A2/pt not_active Application Discontinuation
- 2018-06-06 EP EP18737031.7A patent/EP3634420A1/en not_active Withdrawn
- 2018-06-06 KR KR1020257020007A patent/KR20250099259A/ko active Pending
- 2018-06-06 EP EP24181939.0A patent/EP4410295A3/en active Pending
- 2018-06-06 CA CA3064989A patent/CA3064989A1/en active Pending
-
2019
- 2019-11-25 PH PH12019502651A patent/PH12019502651A1/en unknown
- 2019-12-04 CL CL2019003533A patent/CL2019003533A1/es unknown
- 2019-12-04 IL IL271164A patent/IL271164A/en unknown
- 2019-12-04 MX MX2022015629A patent/MX2022015629A/es unknown
-
2020
- 2020-01-02 ZA ZA2020/00028A patent/ZA202000028B/en unknown
-
2023
- 2023-03-01 JP JP2023030625A patent/JP2023071826A/ja active Pending
-
2024
- 2024-07-03 AU AU2024204591A patent/AU2024204591A1/en active Pending
-
2025
- 2025-01-15 JP JP2025005498A patent/JP2025063196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522560A5 (enExample) | ||
| JP2020523334A5 (enExample) | ||
| US11938139B2 (en) | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2015522630A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| US20210069209A1 (en) | Novel pharmaceutical compositions and methods for menopause related anxiety and depression | |
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| JP2019218379A5 (enExample) | ||
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| JP2016505050A5 (enExample) | ||
| JP2016505561A5 (enExample) | ||
| US20230000882A1 (en) | Novel pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders | |
| CN101932322A (zh) | 用于治疗丙型肝炎病毒感染的包含HMG-CoA还原酶抑制剂和胆汁酸的药物组合物 | |
| US20090118211A1 (en) | Compositions and Methods for Enhancement of Sexual Function | |
| JP2019507786A5 (enExample) | ||
| JP2019535830A5 (enExample) | ||
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| JP5296968B2 (ja) | イブプロフェン含有経口用医薬組成物 | |
| JPWO2023049920A5 (enExample) | ||
| JPWO2021089678A5 (enExample) | ||
| CN115867302A (zh) | 通过抑制白介素-6、TNF-α和其他细胞因子以及通过减少C-反应蛋白来预防和抑制COVID-19发病率和死亡率的方法和化合物 | |
| US12029771B2 (en) | Neem for treatment of RLS | |
| JP4993998B2 (ja) | イブプロフェンを含有する医薬組成物 | |
| NZ759999A (en) | Use of vibegron to treat overactive bladder |